XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS' DEFICIT (Tables)
9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Schedule of Share-Based Payment Arrangement, Cost by Plan
The following table presents the Company's total share based compensation expense by award type:

(In thousands)Three Months Ended
September 30,
Nine Months Ended
September 30,
2024202320242023
RSUs$5,636 $5,112 $15,647 $16,750 
Performance RSUs2,150 2,288 6,351 6,520 
Options477 791 1,965 4,285 
Total Share Based Compensation Expense(1)
$8,263 $8,191 $23,963 $27,555 
(1) Total share based compensation expense includes $1.5 million and $2.0 million of expense from cash settled awards for the three and nine months ended September 30, 2024, respectively. Total share based compensation expense includes $0.4 million and $0.7 million of expense from cash settled awards for the three and nine months ended September 30, 2023, respectively.
Schedule of Computation of Income (Loss) per Share
Computation of Loss per Share
(In thousands, except per share data)Three Months Ended
September 30,
Nine Months Ended
September 30,
 2024202320242023
NUMERATOR:    
Net loss attributable to the Company – common shares$(41,265)$(9,053)$(1,041,431)$(1,115,783)
DENOMINATOR(1):
   
Weighted average common shares outstanding - basic151,990 149,695 150,978 149,084 
  Stock options and restricted stock(2):
— — — — 
Weighted average common shares outstanding - diluted151,990 149,695 150,978 149,084 
Net loss attributable to the Company per common share:   
Basic$(0.27)$(0.06)$(6.90)$(7.48)
Diluted(0.27)(0.06)(6.90)(7.48)
(1) All of the outstanding Special Warrants are included in both the basic and diluted weighted average common shares outstanding of the Company for the three and nine months ended September 30, 2024 and 2023.
(2) Outstanding equity service awards representing 14.8 million and 14.6 million shares of Class A common stock of the Company for the three months ended September 30, 2024 and 2023, respectively, and 15.2 million and 13.3 million for the nine months ended September 30, 2024 and 2023, respectively, were not included in the computation of diluted earnings per share because to do so would have been antidilutive.